1-5 of 5
Xianxian Zheng
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy

Bruno Gomes, Gregory Driessens, Derek Bartlett, Danying Cai, Sandra Cauwenberghs, Stefano Crosignani, Deepak Dalvie, Sofie Denies, Christopher P. Dillon, Valeria R. Fantin, Jie Guo, Marie-Claire Letellier, Wenlin Li, Karen Maegley, Reece Marillier, Nichol Miller, Romain Pirson, Virginie Rabolli, Chad Ray, Nicole Streiner, Vince R. Torti, Konstantinos Tsaparikos, Benoit J. Van den Eynde, Martin Wythes, Li-Chin Yao, Xianxian Zheng, Joseph Tumang, Manfred Kraus
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (12): 2530–2542.
https://doi.org/10.1158/1535-7163.MCT-17-1104
Published: 03 December 2018
View article titled, Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
Open the PDF for Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy in another window
Includes: Supplementary data
Journal Articles

Abstract A42: Palbociclib potentiates nab-paclitaxel efficacy in pancreatic ductal adenocarcinoma

Manuel Hidalgo, Camino Menendez, Jing Yuan, Beatriz Salvador, Tao Xie, John Chionis, Pedro Lopez-Casas, Xianxian Zheng, James Hardwick, Paul Rejto, Peter Olson, Todd VanArsdale, David J. Shields
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A42.
https://doi.org/10.1158/1535-7163.TARG-15-A42
Published: 01 December 2015
View article titled, Abstract A42: Palbociclib potentiates nab-paclitaxel efficacy in pancreatic ductal adenocarcinoma
Journal Articles

Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871)

Adam Pavlicek, Maruja E. Lira, Nathan V. Lee, Keith A. Ching, Jingjing Ye, Joan Cao, Scott J. Garza, Kenneth E. Hook, Mark Ozeck, Stephanie T. Shi, Jing Yuan, Xianxian Zheng, Paul A. Rejto, Julie L.C. Kan, James G. Christensen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (12): 2929–2939.
https://doi.org/10.1158/1535-7163.MCT-13-0442-T
Published: 05 December 2013
View article titled, Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871)
Open the PDF for Molecular Predictors of Sensitivity to the Insulin-like Growth Factor 1 Receptor Inhibitor Figitumumab (CP-751,871) in another window
Includes: Supplementary data
Journal Articles

An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735

Kenneth E. Hook, Scott J. Garza, Maruja E. Lira, Keith A. Ching, Nathan V. Lee, Joan Cao, Jing Yuan, Jingjing Ye, Mark Ozeck, Stephanie T. Shi, Xianxian Zheng, Paul A. Rejto, Julie L.C. Kan, James G. Christensen, Adam Pavlicek
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (3): 710–719.
https://doi.org/10.1158/1535-7163.MCT-11-0184
Published: 06 March 2012
View article titled, An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735
Open the PDF for An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735 in another window
Includes: Supplementary data
Journal Articles

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts

David W. Fry, Patricia J. Harvey, Paul R. Keller, William L. Elliott, MaryAnne Meade, Erin Trachet, Mudher Albassam, XianXian Zheng, Wilbur R. Leopold, Nancy K. Pryer, Peter L. Toogood
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2004) 3 (11): 1427–1438.
https://doi.org/10.1158/1535-7163.1427.3.11
Published: 01 November 2004
View article titled, Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts
Open the PDF for Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts in another window